Pancreatic Cancer Research

ResearcherKochi Health Sciences CenterActive in the last 2 years

Takehiro Okabayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4829-4306; OpenAlex author ID A5051043322. Sources: OpenAlex.

Their work

Papers
20 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers · 2026: 9 papers

Papers 20

  1. Does Recurrent Pancreatic Cancer Have Similar Outcomes Compared With Primary Metastatic Pancreatic Cancer? Last author DOI 10.1002/jso.70222↗
  2. Overcoming cancer resistance in pancreatic cancer: toward dynamic precision oncology. Co-author DOI 10.1007/s11033-026-12767-x↗
  3. Nutritional Therapy in Pancreatic Cancer: Mechanisms, Clinical Applications, and Future Perspectives. Co-author DOI 10.1080/01635581.2026.2698777↗
  4. Redefining Oligometastatic Pancreatic Ductal Adenocarcinoma: Biology, Diagnosis, and Precision Multimodal Therapy. Co-author DOI 10.1080/07357907.2026.2703787↗
  5. Precision Pancreatic Cancer Care: From Early Detection to Adaptive Precision Oncology. Co-author DOI 10.1080/07357907.2026.2721529↗
  6. Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection. Co-author DOI 10.1080/14737140.2026.2709779↗
  7. Revisiting chronic pancreatitis as a risk factor for pancreatic ductal adenocarcinoma: toward precision risk stratification. Co-author DOI 10.1080/17474124.2026.2750981↗
  8. Beyond tumor biology: can host nutritional status refine prediction of early recurrence after pancreatic cancer surgery? Co-author DOI 10.21037/gs-2026-0422↗
  9. Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Co-author DOI 10.3390/cancers18071181↗
  10. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  11. Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Co-author DOI 10.3390/cancers17223694↗
  12. Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. Co-author DOI 10.3390/jcm11226792↗
  13. A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. First author DOI 10.1007/s00423-021-02167-z↗
  14. Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreatic cancer patients. First author DOI 10.1016/j.amjsurg.2019.04.014↗
  15. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer. Co-author DOI 10.1002/1878-0261.12398↗
  16. A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6485-7↗
  17. Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. First author DOI 10.1259/bjr.20170165↗
  18. Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion. Co-author DOI 10.1007/s00423-015-1305-z↗
  19. Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. First author DOI 10.1007/s00423-015-1355-2↗
  20. Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer. Co-author DOI 10.3892/ol.2014.2101↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sunao Uemura · 7 shared papers, 2026 · strength 2.61
  2. Shuta Tamura · 7 shared papers, 2026 · strength 2.61
  3. Kenta Sui · 7 shared papers, 2017–2026 · strength 1.02
  4. Jun Iwata · 8 shared papers, 2015–2026 · strength 0.95
  5. Tatsuo Iiyama · 6 shared papers, 2015–2026 · strength 0.76
  6. Toshiyoshi Fujiwara · 3 shared papers, 2022–2026 · strength 0.61
  7. Yasuhiro Shimada · 5 shared papers, 2017–2022 · strength 0.56
  8. Kazuya Yasui · 2 shared papers, 2025–2026 · strength 0.46
  9. Kosei Takagi · 2 shared papers, 2025–2026 · strength 0.46
  10. Ryuichi Yoshida · 2 shared papers, 2025–2026 · strength 0.46
  11. Manabu Matsumoto · 3 shared papers, 2015–2026 · strength 0.40
  12. Shinya Sakamoto · 1 shared paper, 2026 · strength 0.29
  13. Takatsugu Matsumoto · 2 shared papers, 2020–2021 · strength 0.27
  14. Yasuo Shima · 4 shared papers, 2015–2018 · strength 0.24
  15. Tatsuaki Sumiyoshi · 4 shared papers, 2015–2018 · strength 0.24
  16. Toshiji Saibara · 2 shared papers, 2014–2019 · strength 0.15
  17. Keiichi Kubota · 1 shared paper, 2021 · strength 0.13
  18. Makiko Tsuboi · 1 shared paper, 2019 · strength 0.11
  19. Keisuke Taniuchi · 1 shared paper, 2019 · strength 0.11
  20. Tatsuya Kitagawa · 1 shared paper, 2019 · strength 0.11
  21. Akihito Nishioka · 2 shared papers, 2014–2017 · strength 0.10
  22. Kazuhiro Hanazaki · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.